Stroke, Vol 25, 275-277, Copyright © 1994 by American Heart Association
NM Bornstein, VG Karepov, BD Aronovich, AY Gorbulev, TA Treves and AD Korczyn
BACKGROUND AND PURPOSE: Despite its low efficacy, aspirin is the most
widely used drug for secondary stroke prevention. The reasons why stroke
recurs while patients are on aspirin are unknown. We have analyzed a series
of patients who had recurrent strokes while on aspirin. METHODS: Out of
2231 consecutive patients who were admitted to the Tel Aviv Medical Center
from May 1988 through December 1992 with the diagnosis of ischemic stroke,
129 admissions were due to recurrent ischemic strokes while the patients
were already on aspirin, and these were defined as aspirin failures. The
clinical characteristics of those patients in whom aspirin treatment failed
were compared with three control groups, each comprising 129 patients who
had had only a single ischemic stroke and were then taking aspirin. One
control group was matched for aspirin dose and date of first stroke;
another control group was matched for age, sex, and date of first stroke;
and a third control group was matched for age, sex, date of first stroke,
and aspirin dose. Statistical analysis was carried out by two-tailed
Student's t test and chi 2 test. RESULTS: The average period until stroke
was longer for patients on higher aspirin doses. Patients matched for
aspirin dose and date of first stroke did not differ significantly in age
(72.4 years in aspirin failures versus 74.2 years in the first control
group) and sex (89 versus 94 men, respectively). Matching for age, sex, and
date of first stroke but not for aspirin dose demonstrated a trend toward
high frequency of aspirin failure in patients taking lower doses of aspirin
(chi 2 test for trend = 3.5; P = .06). Comparison of aspirin-failure
patients with a control group matched for age, sex, date of first ischemic
stroke, and aspirin dose demonstrated that these patients more commonly had
statistically significant hyperlipidemia (odds ratio, 2.6; 95% confidence
interval, 1.0 to 6.8; P = .04) and ischemic heart disease (odds ratio, 2.3;
95% confidence interval, 1.3 to 3.9; P = .002). CONCLUSIONS: We conclude
that age and sex do not influence the efficacy of aspirin. Lower aspirin
dose in patients with stroke recurrence suggests that aspirin doses of 500
mg daily or more should be used in secondary stroke prevention.
Hyperlipidemia and ischemic heart disease are risk factors for stroke
recurrence despite aspirin treatment, which requires further clinical and
laboratory evaluation.
ARTICLES
Failure of aspirin treatment after stroke
Department of Neurology, Tel Aviv Medical Center, Israel.
This article has been cited by other articles:
 |
|
 |
|
  C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H Cavallari, C. M Helgason, L. D Brace, M. A. Viana, and E. A Nutescu Sex Difference in the Antiplatelet Effect of Aspirin in Patients with Stroke Ann. Pharmacother., May 1, 2006; 40(5): 812 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Wilterdink, B. Bendixen, H. P. Adams Jr, R. F. Woolson, W. R. Clarke, and M. D. Hansen Effect of Prior Aspirin Use on Stroke Severity in the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Stroke, December 1, 2001; 32(12): 2836 - 2840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119 (2009): 39S - 63S. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sivenius, L. Cunha, H.-C. Diener, C. Forbes, M. Laakso, A. Lowenthal, P. Smets, and P. Riekkinen Sr. Antiplatelet treatment does not reduce the severity of subsequent stroke Neurology, September 1, 1999; 53(4): 825 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Treiman The Natural History of Asymptomatic Carotid Stenosis: Assessing the Risk and Rate of Disease Progression Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1999; 11(2): 95 - 109. [Abstract] [PDF]
|
|
|
|
|
|
L. E. Carlsson, A. Greinacher, C. Spitzer, R. Walther, and C. Kessler Polymorphisms of the Human Platelet Antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the Platelet Receptors for Fibrinogen (GPIIb/IIIa), von Willebrand Factor (GPIb/IX), and Collagen (GPIa/IIa) Are Not Correlated With an Increased Risk for Stroke Stroke, July 1, 1997; 28(7): 1392 - 1395. [Abstract] [Full Text]
|
|
|
|
|
|
C. M. Helgason and P. A. Wolf American Heart Association Prevention Conference IV: Prevention and Rehabilitation of Stroke : Introduction Stroke, July 1, 1997; 28(7): 1498 - 1500. [Full Text]
|
|
|
|
|
|
N. M. Bornstein, B. D. Aronovich, V. G. Karepov, A. Y. Gur, T. A. Treves, M. Oved, and A. D. Korczyn The Tel Aviv Stroke Registry: 3600 Consecutive Patients Stroke, October 1, 1996; 27(10): 1770 - 1773. [Abstract] [Full Text]
|
|
|
|
|
|
R. G. Hart and M. J.G. Harrison Aspirin Wars : The Optimal Dose of Aspirin to Prevent Stroke Stroke, April 1, 1996; 27(4): 585 - 587. [Full Text]
|
|
|
|
 |
|
 P. B. Gorelick Stroke Prevention Arch Neurol, April 1, 1995; 52(4): 347 - 355. [Abstract] [PDF]
|
|
|
|
 |
|
 H. J.M. Barnett, M. Eliasziw, and H. E. Meldrum Drugs and Surgery in the Prevention of Ischemic Stroke N. Engl. J. Med., January 26, 1995; 332(4): 238 - 248. [Full Text] [PDF]
|
|